AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.7000
+0.0085 (1.23%)
At close: Mar 27, 2026, 4:00 PM EDT
0.6951
-0.0049 (-0.70%)
Pre-market: Mar 30, 2026, 7:53 AM EDT
AIM ImmunoTech Employees
As of December 31, 2024, AIM ImmunoTech had 23 total employees, including 21 full-time and 2 part-time employees. The number of employees decreased by 5 or -17.86% compared to the previous year.
Employees
23
Change (1Y)
-5
Growth (1Y)
-17.86%
Revenue / Employee
$3,826
Profits / Employee
-$606,870
Market Cap
2.95M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 23 | -5 | -17.86% | 21 | 2 |
| Dec 31, 2023 | 28 | 4 | 16.67% | 26 | 2 |
| Dec 31, 2022 | 24 | 1 | 4.35% | 22 | 2 |
| Dec 31, 2021 | 23 | 0 | - | 21 | 2 |
| Dec 31, 2020 | 23 | -3 | -11.54% | 21 | 2 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 36 |
| Calidi Biotherapeutics | 28 |
| GeoVax Labs | 17 |
| Dermata Therapeutics | 8 |
| Galmed Pharmaceuticals | 6 |
| Enveric Biosciences | 6 |
| Adial Pharmaceuticals | 5 |
| GRI Bio | 4 |
AIM News
- 11 days ago - AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors - GlobeNewsWire
- 23 days ago - AIM ImmunoTech Announces Closing of its Rights Offering - GlobeNewsWire
- 27 days ago - AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer - GlobeNewsWire
- 4 weeks ago - AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering - GlobeNewsWire
- 4 weeks ago - AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer - GlobeNewsWire
- 6 weeks ago - CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering - GlobeNewsWire
- 6 weeks ago - AIM ImmunoTech Announces Commencement of Rights Offering - GlobeNewsWire
- 7 weeks ago - AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - GlobeNewsWire